Anti-CD33 targeting next-generation DNA-targeting payload antibody-drug conjugates (Pfizer)

N/A

Report date: 2025/03/14 16:41:31

Base Information

Drug NameAnti-CD33 targeting next-generation DNA-targeting payload antibody-drug conjugates (Pfizer)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitors
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A